Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries

K Pritchard-Jones; Rob Pieters; GH Reaman; L Hjorth; P Downie; G Calaminus; MC Naafs-Wilstra; E Steliarova-Foucher

doi:10.1016/S1470-2045(13)70010-X

Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries

K Pritchard-Jones
, Rob Pieters
, GH Reaman
, L Hjorth
, P Downie
, G Calaminus
, MC Naafs-Wilstra
, E Steliarova-Foucher

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

198 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	E95-E103
Journal	Lancet Oncology
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(13)70010-X
Publication status	Published - 2013

Research programs

EMC MM-02-54-03

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(13)70010-X

http://hdl.handle.net/1765/56222

Cite this

@article{08db991f123747eca197e7a2ba11feae,

title = "Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries",

author = "K Pritchard-Jones and Rob Pieters and GH Reaman and L Hjorth and P Downie and G Calaminus and MC Naafs-Wilstra and E Steliarova-Foucher",

year = "2013",

doi = "10.1016/S1470-2045(13)70010-X",

language = "Undefined/Unknown",

volume = "14",

pages = "E95--E103",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries

AU - Pritchard-Jones, K

AU - Pieters, Rob

AU - Reaman, GH

AU - Hjorth, L

AU - Downie, P

AU - Calaminus, G

AU - Naafs-Wilstra, MC

AU - Steliarova-Foucher, E

PY - 2013

Y1 - 2013

U2 - 10.1016/S1470-2045(13)70010-X

DO - 10.1016/S1470-2045(13)70010-X

M3 - Article

C2 - 23434338

SN - 1470-2045

VL - 14

SP - E95-E103

JO - Lancet Oncology

JF - Lancet Oncology

IS - 3

ER -